LONDON (Alliance News) - Biopharmaceutical company Faron Pharmaceuticals Oy on Tuesday said it has enrolled the first patient for the phase 3 clinical trial of Traumakine, its acute respiratory distress syndrome treatment.
Acute respiratory distress syndrome is a severe disease which has a mortality rate of 35% to 40% and for which there is currently no approved pharmalogical treatment, Faron said.
"We believe that Traumakine presents a significant opportunity for those suffering from ARDS, the hospitals which treat them and the societies covering the recovery of ARDS patients," said Faron Chief Executive Markku Jalkanen.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Faron Pharmaceuticals (FARN)